The problem of therapy-resistant depressive disorders in the practice of addiction medicine
Suggested citation:
Polyanskiy DA, Kozhinova TA, Shein VV. [The problem of therapy-resistant depressive disorders in the practice of addiction medicine]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2021;(1):73-81. Russian
This scientific review, pursuing the objective of studying the problem of protracted and treatment-resistant depressive disorders in addiction patients, presents information and research results of domestic and foreign authors on this issue. Failure to provide adequate treatment with available therapy methods to a certain proportion of patients suffering from depressive disorders alongside addictions, as well as absence of outpatient support, which could aid in finding the optimal treatment, in the course of time lead to the development of resistance to therapy in these patients. The topicality of the problem of studying therapy-resistant depressions in the practice of addiction medicine is undeniable, in this regard, there is an urgent need for new approaches and methods of treatment to solve it.
Keywords depressive disorder; addiction disorders; resistance to therapy
1. VOZ. Informacionnyj bjulleten' № 369, Fevral' 2017 g. URL: https://www.who.int/ru/news-room/fact-sheets/detail/depression (accessed: 08.02.2021). (In Russ.) 2. Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065. DOI: https://doi.org/10.1038/nrdp.2016.65; PMID: 27629598 3. Balanza-Martinez V, Crespo-Facorro B, Gonzalez-Pinto A, Vieta E. Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates. Front Physiol. 2015;6:108. DOI: https://doi.org/10.3389/fphys.2015.00108; PMID: 25904869 4. Rozin AI, Roshchina OV, Peshkovskaya AG, Belokrylov II. [Comorbid combinations of alcohol dependence and depressive disorders]. Sibirskij vestnik psihiatrii i narkologii [Siberian Herald of Psychiatry and Addiction Psychiatry]. 2018;4(101):40–5. (In Russ.) DOI: https://doi.org/10.26617/1810-3111-2018-4(101)-40-45 5. Shlemina IV. Klinika i terapiya shizotipicheskogo rasstroistva (maloprogredientnoi shizofrenii), sochetayushchegosya s alkogolizmom. Psihicheskoezdorov'e. 2009;(5):41–8. (In Russ.) 6. Rehm J, Taylor B, Room R. Global burden of disease from alcohol, illicit drugs and tobacco. Drug Alcohol Rev. 2006;25(6):503–13. DOI: https://doi.org/10.1080/09595230600944453; PMID: 17132570 7. Currie SR, Patten SB, Williams JV, et al. Comorbidity of major depression with substance use disorders. Can J Psychiatry. 2005;50(10):660–6. DOI: https://doi.org/10.1177/070674370505001013; PMID: 16276858 8. Davis L, Uezato A, Newell JM, Frazier E. Major depression and comorbid substance use disorders. Curr Opin Psychiatry. 2008;21(1):14–8. DOI: https://doi.org/10.1097/YCO.0b013e3282f32408; PMID: 18281835 9. Abraham HD, Fava M. Order of onset of substance abuse and depression in a sample of depressed outpatients. Compr Psychiatry. 1999;40(1):44–50. DOI: https://doi.org/10.1016/s0010-440x(99)90076-7; PMID: 9924877 10. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730–7. DOI: https://doi.org/10.1016/j.biopsych.2004.06.034; РMID: 15556117 11. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011;106(5):906–14. DOI: https://doi.org/10.1111/j.1360-0443.2010.03351.x; PMID: 21382111 12. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291(15):1887–96. DOI: https://doi.org/10.1001/jama.291.15.1887; PMID: 15100209 13. Nunes EV, Levin FR. Treating depression in substance abusers. Curr Psychiatry Rep. 2006;8(5):363–70. DOI: https://doi.org/10.1007/s11920-006-0037-8 14. Worthington J, Fava M, Agustin C, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996;37(6):518–22. DOI: https://doi.org/10.1016/S0033-3182(96)71515-3; PMID: 8942202 15. Geschwind DH, Flint J. Genetics and genomics of psychiatric disease. Science. 2015;349(6255):1489–94. DOI: https://doi.org/10.1126/science.aaa8954; PMID: 26404826 16. Akil H, Gordon J, Hen R, et al. Treatment resistant depression: A multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272–88. DOI: https://doi.org/10.1016/j.neubiorev.2017.08.019; PMID: 28859997 17. Pougovkina OD, Kholmogorova AB, Tsukarzi EE, et al. [Dynamics of cognitive functioning in patients with resistant depression treated with ECT and the cyclical transcranial magnetic stimulation]. Sotsial'naya i klinicheskaya psikhiatriya [Social and Clinical Psychiatry]. 2006;16(2):47–51. (In Russ.) 18. Ballas C, Staab JP, Evans DL. Strategies for treatment-resistant depression. Psychopharmacol Bull. 2002;36(4):39–62. PMID: 12858144 19. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(13):23–9. PMID: 9402916 20. Nierenberg AA, White K. What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull. 1990;26(4):429–60. PMID: 2087539 21. Bondar' VV. Terapevticheski rezistentnye endogennye depressii (klinika, tipologiya, voprosy patogeneza i lecheniya) [PhD thesis]. [Moscow (Russia)]: Rossiiskaya akademiya med. nauk. Nauch. Tsentr psikhicheskogo zdorov'ya [Russian Academy of Medical Sciences. Mental Health Science Center]; 1992. 22 p. (In Russ.) 22. Lubov EB, Sarkisyan GR. Depressivnie rasstroystva: pharmakon-epidemicheskie I kliniko-ekonomicheskie aspekti. Psichiatria i psichofarmakoterapia [Psychiatry and psychopharmacotherapy]. 2006;2(16):93–100. (In Russ.) 23. Thase ME, Schwartz TL. Choosing medications for treatment-resistant depression based on mechanism of action. J Clin Psychiatry. 2015;76(6):720–7. DOI: https://doi.org/10.4088/JCP.14052ah2c; PMID: 26132673 24. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65(3):341–7. DOI: https://doi.org/10.4088/jcp.v65n0309; PMID: 15096073 25. Bikov UV. Resistentnie k terapii depressii. Stavropol; 2009. 77 p. (In Russ.) 26. Vovin RY. Terapevticheskaya rezistentnost' pri shizofrenii i affektivnykh psikhozakh. Leningrad; 1975. р. 5–13. (In Russ.) 27. Mosolov SN. Rezistentost` k psikhofarmakoterapii. Psichiatria i psichofarmakoterapia [Psychiatry and psychopharmacotherapy]. 2004;2:128–32. (In Russ.) 28. Mosolov SN. Klinicheskoe primenenie sovremenny`x antidepressantov. Saint Petersburg; 1995. 568 p. (In Russ.) 29. Mazo GE, Neznanov NG. Terapevticheski rezistentnye depressii. Saint Petersburg; 2012. 448 p. (In Russ.) 30. Trivedi MH. Treatment-resistant depression: new therapies on the horizon. Ann Clin Psychiatry. 2003;15:59–70. DOI: https://doi.org/10.1023/A:1023232727217; PMID: 12839433 31. Avrutsky GY, Neduva AA. Lechenie psikhicheskikh bol'nykh: Rukovodstvo dlya vrachei. Moscow; 1988. 496 p. (In Russ.) 32. Smulevich AB. Depressii pri somaticheskih I psichicheskich zabolevaniach. Moscow; 2007. 432 р. (In Russ.) 33. Mazo GE, Gorbachev SE, Petrova NN. Terapevticheski rezistentnye depressii: sovremennye podkhody k diagnostike i lecheniyu. Vestnik Sankt-Peterburgskogo Universiteta [Vestniks of Saint Petersburg University]. 2008;2(11):87–96. (In Russ.) 34. Podkorytov VS, Chaika UU. Depressia i rezistentnost`. Zhurnal psichiatrii I medinskoy psichologii [Journal of Psychiatry and Medical Psychology]. 2002;1:118–24. (In Russ.) 35. Vertogradova OP, Petoukhov VV. Zatyazhnie depressii (zakonomernosti fjrmirovania, prognoz, terapiya). Sotsial'naya i klinicheskaya psikhiatriya [Social and Clinical Psychiatry]. 2005;4(15):18–23. (In Russ.) 36. Minutko VL. Depressia. Moscow; 2006. 326 p. (In Russ.) 37. Arushanyan AB. Chronofarmakologia: narubezhe vekov. Stavropol; 2005. 576 p. (In Russ.) 38. Mosolov SN. Klinicheskoe primenenie sovremennih antidepressantov. Russkiy medicinskiy zhurnal [Russian Medical Journal]. 2005;12(13):852–7. (In Russ.) 39. Smulevich AB. Depressia kak obschemedicinskaya problema: voprosi kliniki I terapii. Psichiatria i psichofarmakoterapia [Psychiatry and psychopharmacotherapy]. 2006;3(8):4–10. (In Russ.) 40. Vovin RY, Axenova LI, Kune GE. Farmakoterapevticheskie osnovi reabilitacii psihicheskih bol`nih. Мoscow; 1989. р. 151–81. (In Russ.) 41. Puchkov II. Otkazy ot psikhofarmakoterapii u bol'nykh s nepsikhoticheskimi depressivnymi rasstroistvami [PhD thesis]. [Moscow(Russia)]: Gosudarstvennyi nauchnyi tsentr sotsial'noi i sudebnoi psikhiatrii im. V.P. Serbskogo MZ RF [State Scientific Center for Social and Forensic Psychiatry im. V. Serbsky Ministry of Health of the Russian Federation]; 2005. 28 p. (In Russ.) 42. Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med. 2011;30:22–60. DOI: https://doi.org/10.1159/000324065; PMID: 21508625 43. Russel J. Emotion, core affect, and psychological construction. Cogn Emot. 2009;23(7):1259–83. DOI: https://doi.org/10.1080/02699930902809375 44. Ekkekakis P. The Measurement of Affect, Mood, and Emotion: A Guide for Health-Behavioral Research. Cambridge, UK, New York: Cambridge University Press; 2013. 226 p. 45. Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci. 2008;10(3):291–9. DOI: https://doi.org/10.31887/DCNS.2008.10.3/pgorwood; PMID: 18979942 46. Sternat T, Katzman MA. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr Dis Treat. 2016;12:2149–64. DOI: https://doi.org/10.2147/NDT.S111818; PMID: 27601909 47. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012;35(1):68–77. DOI: https://doi.org/10.1016/j.tins.2011.11.005; PMID: 22177980 48. Snaith RP, Hamilton M, Morley S, at al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99–103. DOI: https://doi.org/10.1192/bjp.167.1.99; PMID: 7551619 49. Huhn AS, Meyer RE, Harris JD, et al. Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. Brain Res Bull. 2016;123:102–9. DOI: https://doi.org/10.1016/j.brainresbull.2015.12.004; PMID: 26711857 50. Garfield JB, Allen NB, Cheetham A, et al. Attention to pleasant stimuli in early adolescence predicts alcohol-related problems in mid-adolescence. Biol Psychol. 2015;108:43–50. DOI: https://doi.org/10.1016/j.biopsycho.2015.03.014 51. Martinotti G, Cloninger CR, Janiri L. Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. Am J Drug Alcohol Abuse. 2008;34(2):177–83. DOI: https://doi.org/10.1080/00952990701877078 52. Cook JW, Spring B, McChargue D, et al. Hedonic capacity, cigarette craving, and diminished positive mood. Nicotine Tob Res. 2004;6(1):39–47. DOI: https://doi.org/10.1080/14622200310001656849; PMID: 14982686 53. Leventhal AM, Waters AJ, Kahler CW, et al. Relations between anhedonia and smoking motivation. Nicotine Tob Res. 2009;11(9):1047–54. DOI: https://doi.org/10.1093/ntr/ntp098; PMID: 19571250 54. Aalto S, Ingman K, Alakurtti K, et al. Intravenous ethanol increases dopamine release in the ventral striatum in humans: PET study using bolus-plus-infusion administration of [(11)C]raclopride. J Cereb Blood Flow Metab. 2015;35(3):424–31. DOI: https://doi.org/10.1038/jcbfm.2014.209; PMID: 25492110 55. Verdejo-Garcia A, Clark L, Verdejo-Román J, et al. Neural substrates of cognitive flexibility in cocaine and gambling addictions. Br J Psychiatry. 2015;207(2):158–64. DOI: https://doi.org/10.1192/bjp.bp.114.152223; PMID: 26045346
DOI: http://dx.doi.org/10.47877/1560-957Х-2021-10108
Article Metrics
Metrics powered by PLOS ALM